Background: Fractures of the lower limbs, including those of the tibia, fibula, femur, and pelvis, are common orthopedic injuries that often result from trauma, falls, or accidents. The study aimed to determine the impact of Teriparatide on clinical and radiological fracture healing parameters.Material and Methods: This interventional study was conducted over 12 months at a tertiary care hospital, enrolling 100 patients aged 18-75 years with lower limb fractures. Patients were randomly assigned to either the Teriparatide group (n=50), receiving daily subcutaneous injections of 20 µg for 12 weeks, or the control group (n=50), receiving standard fracture care. Clinical outcomes, including pain, mobility, and range of motion, were assessed every two weeks for the first three months and then at 6, 9, and 12 months. Radiological healing was monitored using X-rays and the Radiographic Union Score for Tibia (RUST). Functional recovery was measured using the Lower Extremity Functional Scale (LEFS).Results: The Teriparatide group showed significantly lower pain levels (VAS: 2.5 ± 1.2 vs. 4.1 ± 1.5), improved mobility (FMS: 8.7 ± 1.3 vs. 6.4 ± 1.8), and greater range of motion (120.2° ± 12.3° vs. 95.4° ± 13.2°) compared to the control group (p < 0.05 for all). Radiological outcomes showed faster healing in the Teriparatide group, with higher RUST scores at 6 weeks (4.1 ± 1.2 vs. 3.2 ± 1.0), 3 months (6.3 ± 1.3 vs. 5.1 ± 1.5), 6 months (7.8 ± 1.1 vs. 6.6 ± 1.4), and 12 months (9.1 ± 0.9 vs. 7.5 ± 1.3) (p < 0.05 for all). The Teriparatide group also showed faster radiological union (10.2 ± 2.4 weeks vs. 13.5 ± 3.1 weeks) and improved functional recovery (LEFS: 32.4 ± 5.1 vs. 25.6 ± 6.8) (p < 0.05). The incidence of injection site reactions was significantly higher in the Teriparatide group (10% vs. 0%).Conclusion: Teriparatide significantly improves fracture healing in lower limb fractures by accelerating radiological union, reducing pain, enhancing mobility, and improving functional recovery compared to standard care. Although injection site reactions were more common, the overall safety profile was acceptable. These findings support Teriparatide as an effective treatment for fracture recovery.